Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Share News (AVCT)

Share Price Information for Avacta Group (AVCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 46.50
Bid: 46.00
Ask: 47.00
Change: -0.25 (-0.53%)
Spread: 1.00 (2.174%)
Open: 45.75
High: 46.50
Low: 45.50
Prev. Close: 46.75
AVCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK TRADING UPDATE SUMMARY: Omega Wins First Order For Antibody Test

Tue, 09th Jun 2020 11:14

(Alliance News) - The following is a round-up of updates by London-listed companies on the impact of the Covid-19 pandemic, issued on Tuesday and not separately reported by Alliance News:

----------

Avacta Group PLC - Wetherby-based Affimer biotherapeutics developer - Bead-assisted mass spectrometry diagnostics test for Covid-19 infection being developed with partner Adeptrix has reached prototype stage, and can detect the coronavirus spike protein in model sample in the range appropriate for a clinical diagnostic test. Next development step is evaluate and optimise assay before moving to manufacturing and clinical validation.

----------

Omega Diagnostics PLC - Alva-based medical diagnostics - Expects Ebitda for year ended March between GBP850,000 to GBP900,000, ahead of market expectations and up from GBP199,668. Signs long-term supply agreement with Mologic Ltd, for the supply of raw materials for Omega to manufacture its CE-Marked ELISA antibody test. Also signs material transfer agreement with Mologic. Announces first order for test to Senegal worth GBP100,000.

----------

Braveheart Investment Group PLC - Barnsley-based investment holding firm - Paraytec announces that the required affinity macromolecule an aptamer that bonds to the SPIKE glycoprotein on the surface of the Covid-19 virus has been synthesised and supplied to Paraytec from the University of Sheffield. Paraytec expects to complete the production of SPIKE protein in cell factories, and modification of test surface with aptamer in one month.

----------

Ilika PLC - Romsey-based solid-state battery firm - Trading for year ended April 30 in line with expectations. Revenue expected to be GBP2.8 million, up from GBP2.6 million, and narrowed Lbitda of GBP2.1 million from GBP2.2 million. Romsey headquarters remains open throughout lockdown period, while data analytics and business discussions have continued remotely. Expects Stereax pilot line at University of Southampton to reopen shortly.

----------

Sosandar PLC - Cheshire-based women's clothing retail - Reports strong growth in first two months of financial year ending March 31, 2021 despite challenges. Order growth for two months to May 31 up 44% year-on-year, revenue grows by 62%. Increased traffic up 98%, but lower levels of conversion. Marketing expenses reduced, 60% of workforce furloughed, board remuneration reduced. For recently ended year, expects revenue to be at least GBP9 million, up from GBP4.4 million.

----------

SigmaRoc PLC - London-based construction materials - For five months ended May, reports revenue of GBP42 million. In April and May, restriction in Channel Islands lifted allowing Ronez operations to resume more normal trading. In UK, PPG and South Wales platforms scaled up towards full production at end of April and into May. Belgium operations remained active, despite lower activity level.

----------

S&U PLC - Birmingham-based motor finance & property bridging lender - In Advantage Finance, sales for financial year-to-date down to 15% of normal levels due to plummeting car usage, closure of car dealers and ceasing of deliveries, But transactions have now recovered to around 40% of normal. In Aspen Bridging, transaction numbers under a quarter of those budgeted in the year. Improvement seen in both segments.

----------

By Dayo Laniyan; dayolaniyan@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
15 Dec 2021 08:24

Avacta antigen lateral flow test shown to detect Omicron

(Sharecast News) - Aim-listed Avacta said on Wednesday that its AffiDX® antigen lateral flow test has been shown to detect the Omicron variant of the SARS-CoV-2 virus in clinical samples.

Read more
29 Nov 2021 11:07

IN BRIEF: Avacta gets FDA nod to expand cancer drug trial into US

IN BRIEF: Avacta gets FDA nod to expand cancer drug trial into US

Read more
29 Nov 2021 10:38

FDA gives Avacta the go-ahead for US chemotherapy trials

(Sharecast News) - Clinical-stage biopharmaceutical company Avacta Group announced on Monday that the US Food and Drug Administration (FDA) has approved its investigational new drug (IND) application for its chemotherapy drug 'AVA6000'.

Read more
2 Nov 2021 11:25

Avacta and Novacyt await UK regulatory approval for Covid-19 tests

Avacta and Novacyt await UK regulatory approval for Covid-19 tests

Read more
2 Nov 2021 10:21

Avacta suspends UK Covid test sales ahead of new approval

(Sharecast News) - Avacta said on Tuesday that it has suspended sales of its AffiDX Covid latest flow rapid antigen tests in the UK while it awaits new approval.

Read more
30 Sep 2021 11:14

Avacta hails "transformative" first half despite widening loss

Avacta hails "transformative" first half despite widening loss

Read more
30 Sep 2021 09:27

Avacta losses widen as development spend increases

(Sharecast News) - Clinical-stage biopharmaceutical company Avacta Group reported cash and short-term deposits of £37m at the end of its first half on Thursday, down from £54.5m a year ago and £47.9m at the start of the period.

Read more
29 Sep 2021 10:32

Avacta sees pre-clinical development milestone in LG Chem partnership

Avacta sees pre-clinical development milestone in LG Chem partnership

Read more
29 Sep 2021 09:26

Avacta gets undisclosed milestone payment from LG Chem

(Sharecast News) - Clinical-stage biopharmaceutical company Avacta Group announced on Wednesday that a preclinical development milestone has been achieved in its multi-target therapeutics partnership with South Korea's LG Chem Life Sciences, triggering an undisclosed milestone payment.

Read more
23 Sep 2021 15:59

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Read more
2 Sep 2021 11:50

IN BRIEF: Avacta hires oncology drug developer as therapeutics CSO

IN BRIEF: Avacta hires oncology drug developer as therapeutics CSO

Read more
18 Aug 2021 14:26

IN BRIEF: Avacta hires cancer doctor Mark Goldberg for board

IN BRIEF: Avacta hires cancer doctor Mark Goldberg for board

Read more
11 Aug 2021 11:29

Avacta doses first patient in chemotherapy medication trial

Avacta doses first patient in chemotherapy medication trial

Read more
11 Aug 2021 10:00

First patient dosed in Avacta's 'AVA6000' trial

(Sharecast News) - Clinical-stage oncology drug company Avacta Group announced on Wednesday that the first patient has been dosed in its phase 1 multicentre trial evaluating 'AVA6000', which it described as a "novel pro-drug" of 'doxorubicin', and its first therapeutic product based on the proprietary 'preCISION' technology.

Read more
4 Aug 2021 17:53

IN BRIEF: Shipment of Avacta's Covid-19 lateral flow test starts

IN BRIEF: Shipment of Avacta's Covid-19 lateral flow test starts

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.